Abstract:Introduction The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) has gained acceptance in managing diabetic and non-diabetic patients, thanks to its benefits in treating obesity and improving cardiovascular outcomes. The potential ability of GLP-1 RA to cause retained gastric contents (RGC) which can lead to aspiration has led to the recommendation to withhold GLP-1 RA for at least one week prior to elective surgeries and procedures, including upper endoscopies and colonoscopies. However, many co-medications and conditions associated can contribute to delayed gastric emptying (DGE) and these need to be controlled to establish a clear association and incidence, which has been largely missing in most studies and reports. Our aim was to assess clinically significant delayed gastric emptying (CSDGE) related to GLP-1 RA in a "real world" situation by controlling for some common confounding factors. Method We carried out an eight-year retrospective single-center study to assess the relationship between CSDGE and the use of GLP-1 RA among asymptomatic patients undergoing upper endoscopies while controlling for common confounding factors. Result Out of the 3415 patients who had esophagogastroduodenoscopy (EGD) with or without colonoscopy (Ew/woC) during the eight-year period, 129 eligible patients were found to have CSDGE. The use of GLP-1 RA was associated with the lowest percentage frequency distribution of CSDGE, at 2%, and opiate accounted for more percentage frequency distribution, at 35%. The odds ratio for patients on GLP-1 RA who developed CSDGE was 2.5 (95% CI 0.75-8.29). All patients who had CSDGE while on GLP-1 RA were also on other medications or had conditions associated with DGE. Conclusion Our result confirmed the possible effect of confounding factors in the association between CSDGE and GLP-1 RA among asymptomatic patients undergoing Ew/woC. While the need to ensure patients' safety cannot be overemphasized, the proper approach currently favors assessing patients on a case-by-case basis while we await the results of large prospective controlled studies.

S541 Glucagon-Like Peptide-1 Receptor Agonist Use and its Potential Impact in Colonoscopy Among Patients Undergoing Colorectal Cancer Screening: A Multicenter Propensity Score Matching Analysis

S517 The Effect of GLP-1 Receptor Agonists on Bowel Preparation

Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy

S349 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis

S309 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Patients Undergoing Colonoscopy

S862 Impact of GLP-1 Receptor Agonist Indication on Gastric Retention and Boston Bowel Preparatory Score

Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists

S919 Debunking Endoscopy Myths: GLP1-RA Use and GI Symptoms Do NOT Predict Bowel Preparation Success

Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study

Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates On Upper Endoscopy Especially In Complicated Diabetic Patients: A Case Control Study

S920 Clear Liquid Diet and Colonoscopy Bowel Preparation Are Effective in Eliminating Retained Gastric Contents in Those on GLP1-RA Agents Undergoing Endoscopic Procedures

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gastric Mucosal Visibility and Retained Gastric Contents During Esophagogastroduodenoscopy.

Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study

Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review

Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy in Diabetic and Non-Diabetic Patients

Rates Of Repeat Egd In Non-Diabetic Adults With Glucagon-Like-Peptide- 1 Receptor Agonist Prescription: A Retrospective Matched Cohort Study

S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network

The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis

S522 African American Patients Taking GLP-1RA are More Likely to Have Poor Bowel Prep: A Single Center Study

Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists